MIM
KRYS icon

Monashee Investment Management’s Krystal Biotech KRYS Stock Holding History

Monashee Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-35,000
Closed -$1.41M – 153
2019
Q2 		$1.41M Buy
+35,000
New +$1.14M 0.36% 74

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Monashee Investment Management's KRYS Position: Q3 2019 in Review

Monashee Investment Management sold out of Krystal Biotech (KRYS) in Q3 2019, closing a stake of 35,000 shares — an estimated $1.41M sold.

Monashee Investment Management first reported a position in KRYS in Q2 2019 and held it in 1 quarter. The position peaked at $1.41M in Q2 2019. 85 funds tracked by Wall St. Rank hold KRYS as of Q3 2019.

  • Monashee Investment Management reported no remaining Krystal Biotech position as of Q3 2019 after selling out during the quarter.
  • Monashee Investment Management sold 35,000 Krystal Biotech shares in Q3 2019, an estimated $1.41M.
  • Monashee Investment Management first reported a position in Krystal Biotech in Q2 2019 and held it in 1 quarter.
  • Monashee Investment Management's Krystal Biotech position peaked at $1.41M in Q2 2019.
  • 85 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2019.

Based on Monashee Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.